Appropriate diagnostic testing, laboratory screening, or both were needed in patients with suspected occasions. Statistical Analysis The study was designed as an event-driven trial to test the hypothesis that edoxaban would be noninferior to warfarin with respect to the primary efficacy outcome, with an upper limit of the confidence interval for the hazard ratio of just one 1.5 and a two-sided alpha level of 0.05. This margin corresponds to retention of at least 70 percent of the treatment effect of warfarin. Assuming equal efficacy of edoxaban and warfarin, we approximated that 220 events would have to occur for the study to have 85 percent capacity to display the noninferiority of edoxaban.One of the conditions of the FDA authorization is that Gilead must collect viral strains from individuals who become infected with HIV while taking Truvada and test them for any signs of drug resistance, the Wall Street Journal writes . This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an editorially independent news service, is a scheduled program of the Kaiser Family members Foundation, a nonpartisan healthcare policy research organization unaffiliated with Kaiser Permanente.
Acclarent’s new technologies improve visualization during sinus surgery Acclarent, Inc.